H ezode et al. recently reported the frequent occurrence of anemia and thrombocytopenia in the ANRS-CO20-CUPIC cohort of hepatitis C virus (HCV) cirrhotic experienced patients treated with pegylated-interferon (Peg-IFN), ribavirin (RBV), and telaprevir or boceprevir.
In this commentary, we provide results from 15 HCV genotype 1 patients included in the MODCUPIC study, nine receiving telaprevir and six boceprevir. Twelve (80%) were men, with a median (min-max) age of 55 (44-64) years. Eleven patients received Peg-IFN-a2a (eight in telaprevir group, three in boceprevir group), three patients Peg-IFN-a2b (all in boceprevir group), and one patient in the telaprevir group did not receive any injection of Peg-IFN. The observed drug concentrations, the estimated steady-state trough serum concentrations, C ss , and effectiveness EC 50 for all drugs are available in Laou enan et al. 3 Five patients received erythropoietin in supplementation (two in the telaprevir group, three in the boceprevir group) and hemoglobin level and platelet counts were censored afterwards.
RBV-induced anemia modeling
The median (min-max) baseline hemoglobin level was 15.1 g/dl (10.8-16 .0) (15.4 g/dl (10.8-16 .0) in the telaprevir group and 14.5 g/dl (12.6-15.8) in the boceprevir group, P 5 0.3). The hemoglobin level decreased over time in all patients (Supplementary Figures S1 and S2, online) and was well captured by our model (Supplementary Figure S3) . Adding the other drugs, Peg-IFN and protease inhibitors (PIs) did not improve the fit of the data (not shown). There was no significant effect of gender on model parameters. The model predicted that the concentration leading to a 50% blocking effectiveness of RBV in blocking hemoglobin production, IC 50 RBV , was equal to 7,090 ng/ml (Supplementary Table S1 ), leading to a median predicted hemoglobin level at steady state, Hb ss , of 10.0 g/dl (7.8-11.8) (10.6 g/dl (7.8-11.6) in the telaprevir group and 9.1 g/dl (8.0-11.8) in the boceprevir group, P 5 0.5). This corresponds to a median predicted change in hemoglobin level of 4.4 g/dl (2.1-6.6) (4.2 g/dl (2.1-5.5) in the telaprevir group and 4.9 g/dl (3.3-6.6) in the boceprevir group, P 5 0.4). Figure 1a shows the relationship between individual predicted RBV concentration at steady state (C ss RBV ) and effect (blocking production of hemoglobin). For the six patients (40%) who had Hb ss <10 g/ dl (Table 1) , the model predicted that a median RBV dose reduction of 373 mg/day (45-670) would be needed to avoid anemia corresponding to a median dose reduction of 31% (4-67).
Peg-IFN-induced thrombocytopenia modeling
Median baseline platelet counts were 125,500/mm 3 (39,000-230,000) (126,000/mm 3 (67,000-230,000) in Peg-IFN-a2a patients and 80,000/mm 3 (39,000-161,000) in Peg-IFN-a2b patients, P 5 0.4). The platelet counts decreased over time in all patients ( Supplementary Figures S4 and S5) and could be well captured by our model (Supplementary Figure S6) . Adding the other drugs (RBV and PIs) did not improve the fit of the data. The model predicted that the concentration leading to a 50% blocking effectiveness of Peg-IFN in blocking platelets production, IC 50 Peg-IFN , was equal to 104 ng/ml (Supplementary Table S1 ), leading to a median predicted platelet counts at steady state, PLT ss , of 66,720/mm 3 (31,400-121,900) (67,270/mm 3 (39,370-121,900) in Peg-IFN-a2a patients and 60,000/mm 3 (31,400-108,300) in Peg-IFNa2b patients, P 5 0.7), corresponding to a median predicted change in platelet counts of 51,490/mm 3 (16,670- Figure 1b shows the relationship between individual Peg-IFN concentration (C ss Peg-IFN ) and effect (blocking production of platelets). Four patients out of 14 (29%) had predicted PLT ss <50,000/mm 3 using the current dose or Peg-IFN, but one patient had a baseline PLT below 50,000/mm 3 ( Table 1) . For these three patients the model predicted that a median Peg-IFN dose reduction of 37 lg/week (25-37) would be needed to avoid ). Nine patients in the telaprevir group in a (black) and six patients in the boceprevir group (gray). Eleven patients in the Peg-IFN-a2a group in b (black) and three patients in the Peg-IFN-a2b group (gray). The lines denote the predictions with the mean blocking production and the dotted lines denote 95% confidence interval computed with the standard errors predicted by the Fisher Information Matrix. 
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thrombocytopenia, corresponding to a median dose reduction of 60% (57-70).
Towards an approach integrating efficacy and toxicity
The increasing availability of highly effective treatment holds the promise that high rates of sustained virological response (SVR) with lower toxicity can be reached. However, the CUPIC study reporting an incidence of 34.1% and 17.0% for grade 2-4 anemia and grade 3-4 thrombocytopenia, respectively, 1,2 should serve as a reminder that safety may remain an important concern in HCV treatment management, in particular in patients with advanced liver disease whose prevalence in real life is larger than in clinical trials.
Using a model to relate anemia and thrombocytopenia to RBV and Peg-IFN exposure, respectively, we predicted that a dose reduction of RBV and Peg-IFN in 40% and 30% of patients, respectively, would have been needed to avoid toxicity. This would correspond to a median dose reduction of 31% and 60% for RBV and Peg-IFN, respectively. These adjusted RBV and Peg-IFN doses are not practical to administer in actual clinical practice. But here we explore the feasibility and provide an order of magnitude of the amplitude of dose reduction to avoid the occurrence of toxicity.
Because both RBV and Peg-IFN have modest effectiveness against HCV, at least in the first weeks of treatment, where most viruses are sensitive to PIs, 3 this dose reduction is unlikely to have a significant impact on the early viral kinetics. Consistent with this prediction, Poordad et al. showed in a randomized clinical trial that reduction in RBV dosage (up to 50% of the initial amount) throughout the course of triple therapy did not affect SVR rates. 4 Clearly, the small sample size of our population is the main limitation of the study. The lack of statistical power may explain the lack of any significant effect of PI exposure on hemoglobin level and platelet count kinetics. 5, 6 It is well known that RBV causes mainly dose-dependent hemolytic anemia, leading to a reduction in the hemoglobin level, 7 whereas Peg-IFN induces mainly suppression of hematopoiesis, leading to a reduction in platelet counts. 8 This small population also constrained us to analyze the effects of RBV and Peg-IFN separately and independently and we could not evaluate the effect association between the two effects, such as the fact that the bone marrow suppressive effect of Peg-IFN may also contribute to the associated anemia. 9 Both RBV and Peg-IFN concentrations were close to an inhibition effect in hemoglobin level and platelet counts, respectively, equal to 50%. Interestingly, we previously reported that Peg-IFN concentrations in this population also led to an antiviral effect in blocking viral production close to 50%. 3 The fact that Peg-IFN concentrations led to comparable levels of efficacy and toxicity suggests that Peg-IFN has a particularly narrow therapeutic index and reinforces the interest of Peg-IFN therapeutic monitoring in this population. Of note, it should be acknowledged that the effects of RBV and Peg-IFN were described by turnover indirect models with a maximum inhibition of 100% and more data will be needed to evaluate this assumption.
In conclusion, by showing that the serum PK of RBV and Peg-IFN can be used to characterize the kinetics of hemoglobin level and platelet counts, respectively, this study suggests that individual monitoring of the drug concentrations may improve the management of anti-HCV therapy. This approach, combined with a viral kinetic model that can tease out the effect of each drug on the virologic response, 3 holds the promise that integrated model-based approaches could optimize the trade-off between the efficacy and safety of triple therapy. However, this approach will need to be validated on large populations.
Patients and data MODCUPIC is a substudy of the French ANRS-CO20-CUPIC cohort. 3 From September 2011 to September 2012, patients chronically monoinfected with HCV genotype 1, compensated cirrhosis, nonresponders to a prior IFN-based therapy, and who started triple therapy were recruited. Telaprevir-based therapy included 12 weeks of telaprevir (750 mg tid) with Peg-IFN-a2a (180 lg/week) and RBV (1,000 or 1,200 mg/day, depending on body weight), then 36 weeks of Peg-IFN-a2a/RBV. Boceprevir-based therapy included 4 weeks (lead-in phase) of Peg-IFN-a2b (1.5 lg/ kg/week) or Peg-IFN-a2a (180 lg/week) and RBV (800 or 1,400 mg/day, depending on body weight), then 44 weeks of Peg-IFN-a2b/RBV and boceprevir (800 mg tid).
Written informed consent was obtained before enrollment. 
Pharmacokinetic and pharmacodynamic model
We assumed that the changes in hemoglobin level and platelet counts were mainly driven by RBV and Peg-IFN concentrations, respectively. 10 The effects of RBV and Peg-IFN were described by turnover indirect models assuming a maximum inhibition of 100% given by: (t)) is the trough concentration predicted by a PK model previously developed. 3 In brief, C RBV (t) and C Peg-IFN (t) were fitted using an exponential model to obtain the trough concentration at steady state C ss RBV and C ss Peg-IFN . We assumed a linear PK for both drugs. 
Data analysis and parameter estimation

